ipriflavone has been researched along with Bone Loss, Perimenopausal in 42 studies
ipriflavone : A member of the class of isoflavones that is isoflavone in which the hydrogen at position 7 is replaced by an isopropoxy group. A synthetic isoflavone, it was formerly used for the treatment of osteoporosis, although a randomised controlled study failed to show any benefit. It is still used to prevent osteoporosis in post-menopausal women.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ipriflavone, an isoflavone synthesized from the soy isoflavone daidzein, holds great promise in the prevention and treatment of osteoporosis and other metabolic bone diseases." | 4.80 | Ipriflavone: an important bone-building isoflavone. ( Head, KA, 1999) |
| "Ipriflavone could inhibit bone resorption and promote bone formation." | 2.75 | Effects of ipriflavone on postmenopausal syndrome and osteoporosis. ( Dong, CL; Du, J; Li, SW; Wu, JF; Zhang, X; Zhang, YP; Zheng, CX, 2010) |
| " The incidence of adverse reactions in ipriflavone-treated patients (14." | 2.68 | Efficacy of ipriflavone in established osteoporosis and long-term safety. ( Agnusdei, D; Bufalino, L, 1997) |
| "Ipriflavone was administered as oral capsules dosed at 200 mg, 3 times a day for 12 months." | 2.67 | New perspectives in the treatment of postmenopausal osteoporosis: ipriflavone. ( Caserta, D; Moscarini, M; Palermo, P; Patacchiola, F; Spacca, G; Valenti, M, 1994) |
| "In ipriflavone treated group the patterns of biochemical markers indicated that ipriflavone can restrain the bone remodeling processes and radial bone density showed no significant modification during the 12 month study period." | 2.67 | Effects of ipriflavone administration on bone mass and metabolism in ovariectomized women. ( Cappagli, B; Cappelli, N; Felipetto, R; Fioretti, P; Gambacciani, M; Parrini, D; Spinetti, A; Taponeco, F, 1993) |
| " The safety profiles were associated with adverse events and the number of subject withdrawals due to adverse reactions." | 2.66 | The efficacy and safety of ipriflavone in postmenopausal women with osteopenia or osteoporosis: A systematic review and meta-analysis. ( Chen, J; Hu, Q; Huang, S; Long, C; Ning, N; O Klineberg, E; Ran, L; Wu, D; Xu, J; You, X, 2020) |
| "Current therapeutic approaches to postmenopausal bone loss or established osteoporosis vary widely among the different regions of the world." | 2.40 | Miscellaneous and experimental agents. ( Reginster, JY, 1997) |
| "Ipriflavone has been shown to be effective in reducing bone turnover rate mainly through an inhibition of bone resorption, and has been effect to stimulate of bone formation." | 2.40 | [Ipriflavone]. ( Kitatani, K; Morii, H, 1998) |
| "Ipriflavone (IP) is an isoflavone derivative available in several countries for investigational and/or therapeutic use." | 2.38 | Ipriflavone: pharmacological properties and usefulness in postmenopausal osteoporosis. ( Reginster, JY, 1993) |
| "Ipriflavone treatment remarkably prevented osteoporosis via promoting MSCs osteogenesis in ovariectomized rats." | 1.48 | Ipriflavone promotes osteogenesis of MSCs derived from osteoporotic rats. ( Gao, AG; Hu, ZJ; Lu, BB; Zhou, YC, 2018) |
| "Significant inhibition of bone resorption was also seen in intact animals, provided they rapidly ingested the daily meal." | 1.30 | Ipriflavone inhibits bone resorption in intact and ovariectomized rats. ( Cecchini, MG; Fleisch, H; Mühibauer, RC, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 34 (80.95) | 18.2507 |
| 2000's | 5 (11.90) | 29.6817 |
| 2010's | 2 (4.76) | 24.3611 |
| 2020's | 1 (2.38) | 2.80 |
| Authors | Studies |
|---|---|
| Hu, Q | 1 |
| Long, C | 1 |
| Wu, D | 1 |
| You, X | 1 |
| Ran, L | 1 |
| Xu, J | 1 |
| O Klineberg, E | 1 |
| Huang, S | 1 |
| Chen, J | 1 |
| Ning, N | 1 |
| Gao, AG | 1 |
| Zhou, YC | 1 |
| Hu, ZJ | 1 |
| Lu, BB | 1 |
| Zhang, X | 1 |
| Li, SW | 1 |
| Wu, JF | 1 |
| Dong, CL | 1 |
| Zheng, CX | 1 |
| Zhang, YP | 1 |
| Du, J | 1 |
| Ushiroyama, T | 1 |
| Okamura, S | 1 |
| Ikeda, A | 1 |
| Ueki, M | 1 |
| Moscarini, M | 1 |
| Patacchiola, F | 1 |
| Spacca, G | 1 |
| Palermo, P | 1 |
| Caserta, D | 1 |
| Valenti, M | 1 |
| Marsico, S | 1 |
| Scriva, D | 1 |
| Pizzo, A | 1 |
| Grioli, MF | 1 |
| Sodo, G | 1 |
| Valente, M | 1 |
| Bufalino, L | 8 |
| Castiglione, GN | 1 |
| D'Angelo, R | 1 |
| Mancuso, A | 1 |
| Galoppi, P | 1 |
| Zichella, L | 1 |
| Kovács, AB | 1 |
| Reginster, JY | 4 |
| Brandi, ML | 1 |
| Gambacciani, M | 4 |
| Spinetti, A | 1 |
| Cappagli, B | 3 |
| Taponeco, F | 1 |
| Felipetto, R | 1 |
| Parrini, D | 1 |
| Cappelli, N | 1 |
| Fioretti, P | 2 |
| Hanabayashi, T | 1 |
| Imai, A | 1 |
| Tamaya, T | 1 |
| Agnusdei, D | 6 |
| Gennari, C | 7 |
| Cecchettin, M | 1 |
| Bellometti, S | 1 |
| Cremonesi, G | 1 |
| Solimeno, LP | 1 |
| Torri, G | 1 |
| Rodionova, SS | 1 |
| Adami, S | 3 |
| Cervetti, R | 3 |
| Di Marco, C | 2 |
| Di Munno, O | 3 |
| Fantasia, L | 3 |
| Isaia, GC | 3 |
| Serni, U | 2 |
| Vecchiet, L | 2 |
| Passeri, M | 5 |
| Affinito, P | 1 |
| Palomba, S | 1 |
| Sorrentino, C | 1 |
| Pellicano, M | 1 |
| Morgera, R | 1 |
| Nappi, C | 1 |
| Crepaldi, G | 4 |
| Isaia, G | 2 |
| Mazzuoli, G | 2 |
| Ortolani, S | 4 |
| Cecchini, MG | 1 |
| Fleisch, H | 1 |
| Mühibauer, RC | 1 |
| Mazzuoli, GF | 1 |
| Piaggesi, L | 2 |
| Ciaponi, M | 2 |
| Genazzani, AR | 2 |
| Avioli, LV | 1 |
| Christiansen, C | 2 |
| Devogelaer, JP | 2 |
| Riis, BJ | 1 |
| Roux, C | 2 |
| Szántó, F | 1 |
| Choi, YK | 1 |
| Han, IK | 1 |
| Yoon, HK | 1 |
| Kitatani, K | 1 |
| Morii, H | 1 |
| Shiota, E | 1 |
| Head, KA | 1 |
| Ohta, H | 1 |
| Komukai, S | 1 |
| Makita, K | 1 |
| Masuzawa, T | 1 |
| Nozawa, S | 1 |
| Scheiber, MD | 1 |
| Rebar, RW | 1 |
| Halpner, AD | 1 |
| Kellermann, G | 1 |
| Ahlgrimm, MJ | 1 |
| Arndt, CL | 1 |
| Shaikh, NA | 1 |
| Hargrave, JJ | 1 |
| Tallas, PG | 1 |
| Alexandersen, P | 1 |
| Toussaint, A | 1 |
| Fechtenbaum, J | 1 |
| Schelonka, EP | 1 |
| Usher, A | 1 |
| Katase, K | 1 |
| Kato, T | 1 |
| Hirai, Y | 1 |
| Hasumi, K | 1 |
| Chen, JT | 1 |
| Letizia, G | 1 |
| Melis, GB | 1 |
| Paoletti, AM | 1 |
| Bartolini, R | 1 |
| Tosti Balducci, M | 1 |
| Massi, GB | 1 |
| Bruni, V | 1 |
| Becorpi, A | 1 |
| Ottanelli, S | 1 |
10 reviews available for ipriflavone and Bone Loss, Perimenopausal
| Article | Year |
|---|---|
The efficacy and safety of ipriflavone in postmenopausal women with osteopenia or osteoporosis: A systematic review and meta-analysis.
Topics: Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Remodeling; Female; H | 2020 |
Ipriflavone: pharmacological properties and usefulness in postmenopausal osteoporosis.
Topics: Animals; Bone Resorption; Clinical Trials as Topic; Disease Models, Animal; Female; Humans; Hyperpar | 1993 |
New treatment strategies: ipriflavone, strontium, vitamin D metabolites and analogs.
Topics: Aged; Animals; Bone Remodeling; Bone Resorption; Female; Humans; Isoflavones; Osteogenesis; Osteopor | 1993 |
Miscellaneous and experimental agents.
Topics: Anabolic Agents; Animals; Bone Density; Bone Remodeling; Bone Resorption; Estrogen Antagonists; Estr | 1997 |
[Postmenopausal osteoporosis: therapeutic approaches].
Topics: Anabolic Agents; Bone Remodeling; Calcitonin; Calcitriol; Calcium; Diphosphonates; Estrogens; Female | 1997 |
Ipriflavone: background.
Topics: Analgesics; Animals; Bone and Bones; Bone Remodeling; Female; Humans; Isoflavones; Osteoporosis, Pos | 1997 |
The future of ipriflavone in the management of osteoporotic syndromes.
Topics: Bone Density; Bone Remodeling; Female; Humans; Isoflavones; Multicenter Studies as Topic; Osteoporos | 1997 |
[Ipriflavone].
Topics: Bone Remodeling; Female; Humans; Isoflavones; Osteoporosis, Postmenopausal | 1998 |
Ipriflavone: an important bone-building isoflavone.
Topics: Bone Remodeling; Drug Therapy, Combination; Female; Humans; Hyperparathyroidism; Isoflavones; Osteit | 1999 |
Isoflavones and postmenopausal bone health: a viable alternative to estrogen therapy?
Topics: Aged; Animals; Bone Density; Clinical Trials as Topic; Disease Models, Animal; Estrogen Replacement | 1999 |
26 trials available for ipriflavone and Bone Loss, Perimenopausal
| Article | Year |
|---|---|
Effects of ipriflavone on postmenopausal syndrome and osteoporosis.
Topics: Acid Phosphatase; Adult; Alanine Transaminase; Bone Density; Bone Remodeling; Calcium; Double-Blind | 2010 |
Efficacy of ipriflavone and 1 alpha vitamin D therapy for the cessation of vertebral bone loss.
Topics: Drug Therapy, Combination; Female; Humans; Isoflavones; Middle Aged; Osteoporosis, Postmenopausal; V | 1995 |
New perspectives in the treatment of postmenopausal osteoporosis: ipriflavone.
Topics: Administration, Oral; Aged; Bone Density; Female; Humans; Isoflavones; Middle Aged; Osteoporosis, Po | 1994 |
Effects of 1-year treatment with ipriflavone on bone in postmenopausal women with low bone mass.
Topics: Absorptiometry, Photon; Aged; Biomarkers; Bone Density; Bone Resorption; Female; Humans; Isoflavones | 1994 |
Efficacy of ipriflavone in the prevention and treatment of postmenopausal osteoporosis.
Topics: Absorptiometry, Photon; Aged; Bone Density; Double-Blind Method; Female; Humans; Isoflavones; Lumbar | 1994 |
Effects of ipriflavone administration on bone mass and metabolism in ovariectomized women.
Topics: Bone and Bones; Bone Density; Double-Blind Method; Female; Humans; Isoflavones; Middle Aged; Osteopo | 1993 |
Effects of ipriflavone and estriol on postmenopausal osteoporotic changes.
Topics: Bone Density; Estriol; Female; Humans; Isoflavones; Osteoporosis, Postmenopausal | 1995 |
Prevention of early postmenopausal bone loss using low doses of conjugated estrogens and the non-hormonal, bone-active drug ipriflavone.
Topics: Bone Density; Bone Remodeling; Climacteric; Drug Therapy, Combination; Estrogens, Conjugated (USP); | 1995 |
Metabolic and bone effects after administration of ipriflavone and salmon calcitonin in postmenopausal osteoporosis.
Topics: Aged; Aged, 80 and over; Animals; Biomarkers; Bone and Bones; Bone Density; Calcitonin; Female; Huma | 1995 |
[The efficacy of osteoquin in treating the postmenopausal and senile forms of osteoporosis].
Topics: Aged; Analgesics; Bone Density; Bone Remodeling; Female; Humans; Isoflavones; Male; Middle Aged; Ost | 1995 |
Ipriflavone prevents radial bone loss in postmenopausal women with low bone mass over 2 years.
Topics: Aged; Bone and Bones; Bone Density; Female; Humans; Hydroxyproline; Isoflavones; Middle Aged; Osteop | 1997 |
A double blind, placebo-controlled trial of ipriflavone for prevention of postmenopausal spinal bone loss.
Topics: Aged; Bone Remodeling; Double-Blind Method; Female; Humans; Isoflavones; Middle Aged; Osteoporosis, | 1997 |
Effect of chronic treatment with ipriflavone in postmenopausal women with low bone mass.
Topics: Absorptiometry, Photon; Administration, Oral; Aged; Analysis of Variance; Biomarkers; Bone Density; | 1997 |
Efficacy of ipriflavone in established osteoporosis and long-term safety.
Topics: Absorptiometry, Photon; Administration, Oral; Aged; Analysis of Variance; Bone Density; Bone Remodel | 1997 |
Ipriflavone prevents the loss of bone mass in pharmacological menopause induced by GnRH-agonists.
Topics: Absorptiometry, Photon; Analysis of Variance; Antineoplastic Agents, Hormonal; Bone Density; Bone Re | 1997 |
Design for an ipriflavone multicenter European fracture study.
Topics: Absorptiometry, Photon; Aged; Biomarkers; Bone Density; Bone Remodeling; Calcium; Double-Blind Metho | 1997 |
Effects of combined low dose of the isoflavone derivative ipriflavone and estrogen replacement on bone mineral density and metabolism in postmenopausal women.
Topics: Administration, Oral; Adult; Bone Density; Estrogen Replacement Therapy; Estrogens, Non-Steroidal; F | 1997 |
Ipriflavone for the treatment of osteoporosis.
Topics: Alkaline Phosphatase; Bone and Bones; Bone Density; Bone Remodeling; Cells, Cultured; Drug Therapy, | 1997 |
Effect of ipriflavone--a synthetic derivative of natural isoflavones--on bone mass loss in the early years after menopause.
Topics: Administration, Oral; Alkaline Phosphatase; Biomarkers; Bone Density; Calcium; Cohort Studies; Creat | 1998 |
Evaluation of the drug therapy for established osteoporosis by dual-energy x-ray absorptiometry.
Topics: Absorptiometry, Photon; Bone Density; Calcitonin; Calcium Compounds; Female; Humans; Hydroxycholecal | 1998 |
Effects of 1-year ipriflavone treatment on lumbar bone mineral density and bone metabolic markers in postmenopausal women with low bone mass.
Topics: Adult; Biomarkers; Bone Density; Bone Diseases, Metabolic; Female; Humans; Isoflavones; Lumbar Verte | 1999 |
The effect of an ipriflavone-containing supplement on urinary N-linked telopeptide levels in postmenopausal women.
Topics: Biomarkers; Bone Resorption; Calcium; Collagen; Collagen Type I; Dietary Supplements; Disease Progre | 2000 |
Ipriflavone in the treatment of postmenopausal osteoporosis: a randomized controlled trial.
Topics: Aged; Analysis of Variance; Biomarkers; Bone Density; Bone Remodeling; Double-Blind Method; Female; | 2001 |
Effects of ipriflavone on bone loss following a bilateral ovariectomy and menopause: a randomized placebo-controlled study.
Topics: Bone Density; Bone Remodeling; Female; Humans; Isoflavones; Menopause; Middle Aged; Osteoporosis; Os | 2001 |
Effects of ipriflavone on bone mass and calcium metabolism in postmenopausal osteoporosis.
Topics: Aged; Bone Density; Calcium; Double-Blind Method; Female; Humans; Isoflavones; Italy; Middle Aged; O | 1992 |
Ipriflavone and low doses of estrogens in the prevention of bone mineral loss in climacterium.
Topics: Absorptiometry, Photon; Bone Density; Double-Blind Method; Drug Therapy, Combination; Estrogen Repla | 1992 |
6 other studies available for ipriflavone and Bone Loss, Perimenopausal
| Article | Year |
|---|---|
Ipriflavone promotes osteogenesis of MSCs derived from osteoporotic rats.
Topics: Animals; Bone Density; Cell Differentiation; Cells, Cultured; Female; Humans; Isoflavones; Mesenchym | 2018 |
[Postmenopausal osteoporosis. Current therapy protocols].
Topics: Adult; Aged; Calcitonin; Calcium, Dietary; Estrogens; Female; Fluorides; Humans; Isoflavones; Middle | 1994 |
Ipriflavone inhibits bone resorption in intact and ovariectomized rats.
Topics: Administration, Oral; Analysis of Variance; Animals; Bone Remodeling; Bone Resorption; Diet; Disease | 1997 |
[Experience with ipriflavone therapy in postmenopausal osteoporosis].
Topics: Aged; Analgesics; Female; Humans; Isoflavones; Middle Aged; Osteoporosis, Postmenopausal; Pain | 1997 |
Ipriflavone not effective for osteoporosis.
Topics: Aged; Bone Density; Female; Fractures, Bone; Humans; Isoflavones; Middle Aged; Osteoporosis, Postmen | 2001 |
Ipriflavone and osteoporosis.
Topics: Bone Remodeling; Female; Humans; Isoflavones; Osteoporosis, Postmenopausal | 2001 |